| ¿µ¹® | systemic lupus erythematosus | ÇÑ±Û | Àü½ÅÈ«¹Ý·çǪ½º |
|---|---|---|---|
| ¼³¸í | Àü½Å ÀÚ°¡¸é¿ªº´ÀÇ ´ëÇ¥Àû º´ÀÌ´Ù. ¿©¼º¿¡°Ô ¾ÐµµÀûÀ¸·Î ¸¹°í, 10~39¼¼±îÁö°¡ 70%¸¦ Â÷ÁöÇÑ´Ù. ¿øÀÎÀº Àß ¸ð¸£³ª ÀÚ°¡¸é¿ª Á¶Àý±â´É¿¡ Àå¾Ö°¡ ÀÖ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù. À¯Àü¿äÀÎ, È£¸£¸óÀÇ ¿µÇâ, ȯ°æ¿ä¼Ò°¡ Á¾ÇÕÀûÀ¸·Î º¸Á¶ T¼¼Æ÷¿Í B¼¼Æ÷¸¦ Ȱ¼ºÈ½ÃÄѼ ¿©·¯ °¡Áö ÀÚ°¡Ç×üµé, Áï õ¿¬ DNA, ÀÌÁß°¡´Ú DNA, ¿Ü°¡´Ú DNA, RNA, ÇٴܹéÁú µî°ú °°Àº ÇÙ Ç׿ø¿¡ ´ëÇÑ Ç×ü, ºñÇÙÇ׿ø¿¡ ´ëÇÑ ¿©·¯ °¡Áö Ç×ü°¡ ½ñ¾ÆÁ® ³ª¿Â´Ù. ÀÌ Áß ÀÌÁß°¡´Ú DNA¸¦ Æ÷ÇÔÇÑ ¼øÈ¯¸é¿ªº¹ÇÕü°¡ ÄáÆÏ¿¡ Ä§ÂøÇÏ¿© ¼Õ»óÀ» ÀÏÀ¸Å°´Âµ¥ °ü¿©ÇÑ´Ù. DNA¿Í ¿©·¯ °¡Áö ¼¼Æ÷¼ººÐ¿¡ ´ëÇÑ ÀÚ°¡¸é¿ªÁúȯÀ¸·Î ÀüÄáÆÏ±â¸¦ ħ¹üÇÏ¿© ¿°ÁõÀ» ÀÏÀ¸Å²´Ù. ¿©·¯ ÀÚ°¡Ç׿ø¿¡ ´ëÇÑ ¸é¿ª¹ÝÀÀ¿¡ ÀÇÇÑ Ç×üÀÇÁ¸¼º ¸é¿ª¹ÝÀÀ°ú ¸é¿ªº¹ÇÕü ¹ÝÀÀÀ¸·Î Å丮ÄáÆÏ¿°, Ç÷°ü¿°, °üÀý¿° ¹× ºóÇ÷À» µ¿¹ÝÇÑ´Ù. |
||
| ¿µ¹® | testicular feminization syndrome | ÇÑ±Û | °íȯ¿©¼ºÈÁõÈıº |
|---|---|---|---|
| ¼³¸í | ÀÌÂ÷¼ºÀåÀ» Æ÷ÇÔÇÏ¿©, ¿Ü¼º±âÀÇ ¹ßÀ°Àº ¿©¼ºÀÌÁö¸¸ °íȯÀÌ Á¸ÀçÇϰí, Àڱðú ÀڱðüÀÌ °áÇ̵Ǿî ÀÖ´Â ³²¼º °ÅÁþ³²³àÇѸöÁõÀÇ ±Ø´ÜÀû ÇüÅÂÀÌ´Ù. À̰ÍÀº Å×½ºÅ佺Å×·ÐÀÇ ÀÛ¿ë¿¡ ´ëÇÑ ¸»´Ü±â°üÀÇ ÀúÇ׿¡ ±âÀÎÇÑ´Ù. |
||
| ¿µ¹® | irritable bowel syndrome | ÇÑ±Û | °ú¹Î¼º´ëÀåÁõÈıº |
|---|---|---|---|
| ¼³¸í | ¹èº¯Àå¾Ö, º¹Åë, º¹ºÎÆØ¸¸ µîÀÇ Áõ»óÀÌ ÀÖÀ¸³ª ±âÁúÀûÀÎ º´º¯ÀÌ ¾øÀ½ÀÌ È®ÀÎµÈ ¿¹¸¦ ÃѸÁ¶óÇÑ ÀÓ»ó ÁõÈıºÀÌ´Ù. °¡Àå ÈçÇÑ ¼Òȱâ ÁúȯÀ̸ç(Àü¼Òȱâ ȯÀÚÀÇ 70~80%) °¡Àå ÈçÇÑ Áúº´(Àüü Àα¸ÀÇ ¾à 20%)ÀÌ´Ù. ¿©¼ºÀÌ ³²¼º¿¡ ºñÇØ 2¹è Á¤µµ ¸¹ÀÌ ¹ß»ýÇϸç 30´ë ¹× 40´ë¿¡¼ È£¹ßÇÏ°í ¼±Áø °ø¾÷±¹¿¡¼ ¸¹ÀÌ ¹ß»ýÇÑ´Ù. Áø´ÜÀ» À§Çؼ´Â º´·Â ûÃë°¡ °¡Àå Áß¿äÇÏ°í °¢Á¾ °Ë»ç·Î¼ ±âÁúº´À» Á¦¿ÜÇØ¾ß ÇÑ´Ù. Ä¡·á·Î´Â ¾ÈÁ¤¿ä¹ý(Á¤½Å°úÀû ¸é´ã ¹× ½É¸®¿ä¹ý, ½Å°æ¾ÈÁ¤Á¦), ½Ä»ç¿ä¹ý(°í¼¶À¯Áú À½½Ä ¼·Ãë, Àڱؼº À½½Ä ÇÇÇϱâ), ¾à¹° ¿ä¹ý(âÀÚ°æ·Ã ÁøÁ¤Á¦, º¯ºñ ¿ÏÈÁ¦, Áö»çÁ¦) µîÀ» »ç¿ëÇÑ´Ù. |
||
| ¿µ¹® | withdrawal syndrome | ÇÑ±Û | ±Ý´ÜÁõÈı٠|
|---|---|---|---|
| ¼³¸í | ¾ËÄÚ¿Ã, ¸¶¾à, ¹ÙºñÅõ¸£»ê°è ÃÖ¸é¾à µîÀÇ ¾à¹°À» Àå±â°£ º¹¿ëÇÏ¿© ¾à¹°ÀÌ ¾øÀÌ´Â °ßµô ¼ö ¾ø°ÔµÈ µÚ, ±× ¾à¹°À» ÁßÁöÇÑ °æ¿ì¿¡ ³ªÅ¸³ª´Â, °íÅëÀÌ ¼ö¹ÝµÇ´Â ½ÅüÀû Áõ»óÀ» ¸»ÇÑ´Ù. ¿¬¼Ó º¹¿ëÀÇ ±â°£¿¡ µû¶ó Áõ»óÀÌ ¹«°Å¿öÁø´Ù. Åë»óÀûÀ¸·Î ±¸Åä, ¼³»ç, Ç÷¾Ð»ó½Â, ºü¸¥¸Æ, ¶¡³², È¥¼ö µîÀÇ Áõ»óÀÌ ³ªÅ¸³´Ù. |
||
| ¿µ¹® | organic brain syndrome | ÇÑ±Û | ±âÁúÀû ³úÁõÈıº |
|---|---|---|---|
| ¼³¸í | ³úÀÇ ±âÁúÀûÀÎ(organic-:ÀÌ ¸»Àº ±â´ÉÀûÀÎ(functional)¿¡ ¹ÝÇÏ´Â ¸»·Î½á) ¸ðµç °Ë»ç¸¦ ½ÃÇàÇÏ¸é ¾î¶² ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ÀÖ´Ù´Â ¶æÀÌ´Ù. ¹Ù²Ù¾î ¸»Çϸé, ±â´ÉÀûÀÎ ÀÌ»ó¿¡ ÀÇÇÑ ³úÁõÈıºÀº ¾î¶°ÇÑ °Ë»ç·Îµµ ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ¾øÀ¸³ª ºÐ¸íÈ÷ ȯÀÚ¿¡°Ô ÀÌ»óÁõ»óÀÌ ³ªÅ¸³µÀ» ¶§ À̸¦ ¹¾î¼ ¸»ÇÑ´Ù. ÀÌ»ó¿¡ ÀÇÇØ ½Å°æÇÐÀûÀÎ ÀÌ»óÀ» ³ªÅ¸³»´Â ÀÏ·ÃÀÇ º´ÀûÇö»óÀ» ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ÀÌ º´Àº ÈçÈ÷ º¸¾Æ ¸¶Ä¡ Á¤½Åº´È¯ÀÚó·³ ¸»À» Ⱦ¼³¼ö¼³Çϰí, ¾Ë¾ÆµéÀ» ¼ö ¾ø´Â ¸»À» Çϸç, ¶§·Î´Â ´Ù¸¥ »ç¶÷¿¡°Ô °ø°ÝÀûÀÎ ¼ºÇâÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×¸®°í ´Ù¸¥ »ç¶÷°ú µµÀúÈ÷ ±³·ù¸¦ ÇÒ ¼ö ¾ø´Â Á¤¼¸¦ ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×·¯³ª, ÀÌ º´ÀÌ ´Ù¸¥ Á¤½Åº´°ú ±¸º°µÇ´Â Ư¡ÀûÀÎ Áõ»óÀº ¸ÕÀú, ÀǽÄÀÇ È¥Å¹ÀÌ µ¿¹ÝµÇ´Â °æ¿ì°¡ ¸¹°í, ¶ÇÇÑ ±× Áõ»óÀÇ Á¤µµ°¡ º¯ÇÑ´Ù´Â °ÍÀÌ´Ù. Áï, ¾ÆÄ§¿¡´Â Á¤»óÀûÀÎ ÇൿÀ» ÇÏ´Ù°¡ ¿ÀÈİ¡ µÇ¸é, ÀǽÄÀÌ Èå·ÁÁö¸é¼ ¸»À» Ⱦ¼³¼ö¼³ÇÑ´Ù¸é, ÀÌ´Â ±âÁú¼º³úÁõÈıºÀÏ °¡´É¼ºÀÌ ³ô´Ù. |
||
| LA | lactic acid; large amount; laser angioplasty; late abortion; late antigen; latex agglutination; left... |
|---|---|
| LAC | La Crosse [virus]; lactase; left atrial circumflex [artery]; left atrial contraction; linguoaxiocerv... |
| DLE | delayed light emission; dialyzable leukocyte extract; discoid lupus erythematosus; disseminated lupu... |
| MS | Maffuci syndrome; maladjustment score; mandibular series; Marfan syndrome; Marie-Strumpell [syndrome... |
| CS | calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ... |
| LAC | Lupus AntiCoagulant |
|---|---|
| AC | Anticoagulant |
| OAC | Oral anticoagulant |
| OAT | Oral anticoagulant therapy |
| r-TAP | Recombinant tick anticoagulant peptide |
| lupus anticoagulant | An immunoglobulin that interferes with blood coagulation and has antithromboplastin activity. This immunoglobulin can prolong blood clotting and occurs in approximately 25% of people with lupus. (27 Sep 1997) |
|---|---|
| anticoagulant | <haematology, pharmacology> Any substance that prevents blood clotting. Those drugs administered for prophylaxis or treatment of thromboembolic disorders are heparin, which inactivates thrombin and several other clotting factors and which must be administered parenterally and the oral anticoagulants (warfarin, dicumarol and congeners) which inhibit the hepatic synthesis of vitamin K dependent clotting factors. Anticoagulant solutions used for the preservation of stored whole blood and blood fractions are acid citrate dextrose (ACD), citrate phosphate dextrose (CPD), citrate phosphate dextrose adenine (cPDA 1) and heparin. Anticoagulants used to prevent clotting of blood specimens for laboratory analysis are heparin and several substances that make calcium ions unavailable to the clotting process, including EDTA (ethylenediaminetetraacetic acid), citrate, oxalate and fluoride. (18 Nov 1997) |
| anticoagulant therapy | The use of anticoagulant drugs to reduce or prevent intravascular or intracardiac clotting. (05 Mar 2000) |
| vascular anticoagulant | <protein> Group of calcium-binding proteins that interact with acidic membrane phospholipids in membranes. They contain 4 or 8 repeats of a 61 amino acid domain that folds into 5 a helices. Also known by several other names (e.g. Lipocortins, endonexins), reflecting the history of their discovery in different contexts. See: lipocortin, endonexin I & II, calpactin, p70 and calelectrin. (18 Nov 1997) |
| lupus-like syndrome | <syndrome> A clinical syndrome resembling that of systemic lupus erythematosus, but due to some other cause. (05 Mar 2000) |
| panniculitis, lupus erythematosus | A type of lupus erythematosus characterised by deep dermal or subcutaneous nodules, most often on the head, face, or upper arms. It is generally chronic and occurs most often in women between the ages of 20 and 45. (12 Dec 1998) |
| chilblain lupus | Skin lesions seen in patients with lupus erythematosus, resembling the small, hardened nodular areas of a cold injury called chilblains. Synonym: chilblain lupus. (05 Mar 2000) |
| chilblain lupus erythematosus | Skin lesions seen in patients with lupus erythematosus, resembling the small, hardened nodular areas of a cold injury called chilblains. Synonym: chilblain lupus. (05 Mar 2000) |
| chronic discoid lupus erythematosus | A form of lupus erythematosus in which cutaneous lesions are present; these commonly appear on the face and are atrophic plaques with erythema, hyperkeratosis, follicular plugging, and telangiectasia; in some instances systemic lupus erythematosis may develop. Synonym: chronic discoid lupus erythematosus. (05 Mar 2000) |
| cutaneous lupus erythematosus | Skin disease seen in patients with discoid form of lupus erythematosus, a term for a variety of skin lesions seen in systemic lupus erythematosus. (05 Mar 2000) |
| neonatal lupus | Lupus erythematosus occurring in newborn children of mothers who had lupus during pregnancy; anti-SSA antibodies usually should be screened for; 50% have anti-nuclear antibodies. A variety of skin lesions are seen, which can resolve or leave scarring; the syndrome usually resolves; however cardiac manifestations can be fatal. Some children develop systemic lupus later in life. (05 Mar 2000) |
| systemic lupus erythematosus | <immunology, nephrology, rheumatology> A disease of humans, probably autoimmune with antinuclear and other antibodies in plasma. Immune complex deposition in the glomerular capillaries is a particular problem. Acronym: SLE (19 Jan 1998) |
| discoid lupus erythematosus | A form of lupus erythematosus in which cutaneous lesions are present; these commonly appear on the face and are atrophic plaques with erythema, hyperkeratosis, follicular plugging, and telangiectasia; in some instances systemic lupus erythematosis may develop. Synonym: chronic discoid lupus erythematosus. (05 Mar 2000) |
| disseminated lupus erythematosus | <immunology, nephrology, rheumatology> A disease of humans, probably autoimmune with antinuclear and other antibodies in plasma. Immune complex deposition in the glomerular capillaries is a particular problem. Acronym: SLE (19 Jan 1998) |
| drug-induced lupus | <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug. Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine. The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare. Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections. (18 Jul 2002) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|